A study performed by Zanchi et al. in 2013 showed that angiotensin-converting enzyme (ACE) inhibitors protect against kidney damage in patients with DN not only by reducing blood pressure but also by modulating plasma levels of FGF23 and its secretion in the kidney [34]. This evidence concerns the gene ACE and liver dysplastic nodule.